Investors need to pay close attention to BCRX stock based on the movements in the options market lat

BioCryst Pharmaceuticals (NASDAQ:BCRX) closed at $9.84 on August 10, 2026, giving the Durham-based r

RBC Capital analyst Brian Abrahams maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and

Wedbush analyst Laura Chico maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and lowers

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2026 Earnings Call Transcript

BioCryst Pharmaceuticals NASDAQ: BCRX reported second-quarter results marked by growth in ORLADEYO r

BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $0.3 per share, beating the Zack

BioCryst Pharma (NASDAQ:BCRX) affirms FY2026 sales outlook from $635.000 million-$660.000 million to

— Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating pro

ADAR1 Capital Management LLC boosted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDA

RESEARCH TRIANGLE PARK, N.C., July 22, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasd

RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasd

The consensus price target hints at an 118% upside potential for BioCryst (BCRX). While empirical re

JP Morgan analyst Jessica Fye reinstates BioCryst Pharma (NASDAQ:BCRX) with a Neutral and announc

BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend

RESEARCH TRIANGLE PARK, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasd

BioCryst Pharmaceuticals said on Monday it would wind down its internal drug discovery programs and

—Advances strategic shift toward a disciplined research model prioritizing external innovation to ac

BioCryst Pharmaceuticals, Inc. is upgraded to Buy, reflecting strong execution in HAE and a compelli

— Growing body of ORLADEYO ® clinical data and real-world evidence demonstrates consistent reduction

RESEARCH TRIANGLE PARK, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasd

RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasda

RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasda

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Bank of America Global Healthcare Conference 2026

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) reported upbeat earnings for the first quarter on Wednesd

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2026 Earnings Call Transcript

PAVS stock rose 65.6% in pre-market trading after ending sales agreement with A.G.P/Alliance Global

Retail investors are preparing for another busy week of earnings season with more than 1,600 compani

FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and s

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly ear

Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly ear

  Tuesday saw 132 companies set new 52-week lows.

  On Thursday, 369 companies hit new 52-week lows.

  On Tuesday, 647 companies set new 52-week lows.

  During Tuesday's trading, 188 companies set new 52-week lows.

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings

  On Tuesday, 91 stocks hit new 52-week lows.

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is likely to report earnings for its f

Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.

Upgrades

  Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for

  On Wednesday, 807 companies reached new 52-week lows.

  On Friday, 1043 companies hit new 52-week lows.